Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025
Press Releases
April 28, 2025

Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025

SHANGHAI, April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today announced it

bradford

The Bradford Era

Local & Social